Efficacy of low-dose D₂/D₃ partial agonist pramipexole on neuroleptic-induced extrapyramidal symptoms and symptoms of schizophrenia: a stage-1 open-label pilot study

References

• Divac N, Prostran M, Jakovcevski I, Cerovac N. Second-generation antipsychotics and extrapyramidal adverse effects. Biomed Res Int. 2014;2014:656370. doi:10.1155/2014/65637024995318
   PubMed Web of Science ®Google Scholar
• Mehta SH, Morgan JC, Sethi KD. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Neurol Clin. 2015;33(1):153–174. doi:10.1016/j.ncl.2014.09.01125432728
   PubMed Web of Science ®Google Scholar
• Miller DD, McEvoy JP, Davis SM, et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res. 2005;80(1):33–43. doi:10.1016/j.schres.2005.07.03416171976
   PubMed Web of Science ®Google Scholar
• Mentzel TQ, Lieverse R, Bloemen O, Viechtbauer W, van Harten PN, Incidence H. Prevalence of drug-related movement disorders in young patients with psychotic disorders. J Clin Psychopharmacol. 2017;37(2):231–238. doi:10.1097/JCP.000000000000066628141621
   PubMed Web of Science ®Google Scholar
• Park IJ, Jung DC, Hwang SS, et al. The longitudinal trends in the relationship between drug-induced extrapyramidal symptoms and personal and social performance in a population of the patients with schizophrenia: A latent growth model. Psychiatry Res. 2016;238:33–39. doi:10.1016/j.psychres.2016.01.06927086208
   PubMed Web of Science ®Google Scholar
• Su YA, Yan F, Li Q, et al. Anticholinergic use trends in 14,013 patients with schizophrenia from three national surveys on the use of psychotropic medications in China (2002–2012). Psychiatry Res. 2017;257:132–136. doi:10.1016/j.psychres.2017.07.03828755603
   PubMed Web of Science ®Google Scholar
• Pristed SG, Correll CU, Nielsen J. Frequency and correlates of anticholinergic use among patients with schizophrenia in Denmark: a nation-wide pharmacoepidemiological study. Psychiatry Res. 2017;255:198–203. doi:10.1016/j.psychres.2017.05.03328578178
   PubMed Web of Science ®Google Scholar
• Vinogradov S, Fisher M, Warm H, Holland C, Kirshner MA, Pollock BG. The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. Am J Psychiatry. 2009;166(9):1055–1062. doi:10.1176/appi.ajp.2009.0901001719570929
   PubMed Web of Science ®Google Scholar
• Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull. 2010;36(1):94–103. doi:10.1093/schbul/sbp13019955388
   PubMed Web of Science ®Google Scholar
• Oertel W, Schulz JB. Current and experimental treatments of Parkinson disease: A guide for neuroscientists. J Neurochem. 2016;139(Suppl 1):325–337. doi:10.1111/jnc.1375027577098
   PubMed Web of Science ®Google Scholar
• Mehta SH, Morgan JC, Sethi KD. Drug-induced movement disorders. Neurol Clin. 2015;33(1):153–174. doi:10.1016/j.ncl.2014.09.01125432728
   PubMed Web of Science ®Google Scholar
• Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry. 2000;57(6):553–559.10839333
   PubMed Web of Science ®Google Scholar
• Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(6):573–580. doi:10.1016/S1474-4422(10)70106-X20452823
   PubMed Web of Science ®Google Scholar
• Berghauzen-Maciejewska K, Kuter K, Kolasiewicz W, et al. Pramipexole but not imipramine or fluoxetine reverses the “depressive-like” behaviour in a rat model of preclinical stages of Parkinson’s disease. Behav Brain Res. 2014;271(1):343-353 doi: 10.1016/j.bbr.2014.06.029.
   Google Scholar
• Kasper S, Barnas C, Heiden A, et al. Pramipexole as adjunct to haloperidol in schizophrenia. Safety and efficacy. Eur Neuropsychopharmacol. 1997;7(1):65–70.9088887
   PubMed Web of Science ®Google Scholar
• Nemeth G, Laszlovszky I, Czobor P, et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet (London, England). 2017;389(10074):1103–1113. doi:10.1016/S0140-6736(17)30060-0
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 2011.
   Google Scholar
• Clarke CE, Guttman M. Dopamine agonist monotherapy in Parkinson’s disease. Lancet (London, England). 2002;360(9347):1767–1769. doi:10.1016/s0140-6736(02)11668-0
   Web of Science ®Google Scholar
• Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica Supplementum. 1970;212:11–19.4917967
   PubMedGoogle Scholar
• Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672–676. doi:10.1192/bjp.154.5.6722574607
   PubMed Web of Science ®Google Scholar
• Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr Res. 1990;3(4):247–251.2278986
   PubMed Web of Science ®Google Scholar
• Addington D, Addington J, Maticka-Tyndale E, Joyce J. Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res. 1992;6(3):201–208.1571313
   PubMed Web of Science ®Google Scholar
• Haro JM, Kamath SA, Ochoa S, et al.The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr ScandSuppl. 2003;(416):16–23. doi:10.1034/j.1600-0447.107.s416.5.x
   Web of Science ®Google Scholar
• Di Fabio R, De Filippis S, Cafariello C, et al. Low doses of rotigotine in patients with antipsychotic-induced parkinsonism. Clin Neuropharmacol. 2013;36(5):162–165. doi:10.1097/WNF.0b013e3182a2ce3f24045607
   PubMed Web of Science ®Google Scholar
• Ferger B, Buck K, Shimasaki M, Koros E, Voehringer P, Buerger E. Continuous dopaminergic stimulation by pramipexole is effective to treat early morning akinesia in animal models of Parkinson’s disease: a pharmacokinetic-pharmacodynamic study using in vivo microdialysis in rats. Synapse (New York, NY). 2010;64(7):533–541. doi:10.1002/syn.v64:7
   PubMed Web of Science ®Google Scholar
• Castro-Hernandez J, Afonso-Oramas D, Cruz-Muros I, et al. Prolonged treatment with pramipexole promotes physical interaction of striatal dopamine D3 autoreceptors with dopamine transporters to reduce dopamine uptake. Neurobiol Dis. 2015;74(2):325–335. doi:10.1016/j.nbd.2014.12.00725511804
   PubMed Web of Science ®Google Scholar
• Kharkwal G, Brami-Cherrier K, Lizardi-Ortiz JE, et al. Parkinsonism driven by antipsychotics originates from dopaminergic control of striatal cholinergic interneurons. Neuron. 2016;91(1):67–78. doi:10.1016/j.neuron.2016.06.01427387649
   PubMed Web of Science ®Google Scholar
• Wang Y, Yu X, Zhang P, et al. Neuroprotective effects of pramipexole transdermal patch in the MPTP-induced mouse model of Parkinson’s disease. J Pharmacol Sci. 2018;138(1):31–37. doi:10.1016/j.jphs.2018.08.00830241783
   PubMed Web of Science ®Google Scholar
• Shibagaki K, Okamoto K, Katsuta O, Nakamura M. Beneficial protective effect of pramipexole on light-induced retinal damage in mice. Exp Eye Res. 2015;139:64–72. doi:10.1016/j.exer.2015.07.00726213307
   PubMed Web of Science ®Google Scholar
• Juncal-Ruiz M, Ramirez-Bonilla M, Gomez-Arnau J, et al. Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment. Psychopharmacology. 2017;234(17):2563–2570. doi:10.1007/s00213-017-4646-128567698
   PubMed Web of Science ®Google Scholar
• Brust TF, Hayes MP, Roman DL, Watts VJ. New functional activity of aripiprazole revealed: robust antagonism of D2 dopamine receptor-stimulated Gbetagamma signaling. Biochem Pharmacol. 2015;93(1):85–91. doi:10.1016/j.bcp.2014.10.01425449598
   PubMed Web of Science ®Google Scholar
• Stahl SM. Mechanism of action of cariprazine. CNS Spectr. 2016;21(2):123–127. doi:10.1017/S109285291600004326956157
   PubMed Web of Science ®Google Scholar
• Chernoloz O, El Mansari M, Blier P. Sustained administration of pramipexole modifies the spontaneous firing of dopamine, norepinephrine, and serotonin neurons in the rat brain. Neuropsychopharmacology. 2009;34(3):651–661. doi:10.1038/npp.2008.11418688211
   PubMed Web of Science ®Google Scholar
• Kelleher JP, Centorrino F, Huxley NA, et al. Pilot randomized, controlled trial of pramipexole to augment antipsychotic treatment. Eur Neuropsychopharmacol. 2012;22(6):415–418. doi:10.1016/j.euroneuro.2011.10.00222153972
   PubMed Web of Science ®Google Scholar
• Cusin C, Iovieno N, Iosifescu DV, et al. A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder. J Clin Psychiatry. 2013;74(7):e636–e641. doi:10.4088/JCP.12m0809323945458
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr., Payne JL, Singh J, et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry. 2004;56(1):54–60. doi:10.1016/j.biopsych.2004.03.01315219473
   PubMed Web of Science ®Google Scholar